Prostate-specific membrane antigen (PSMA)-targeting CAR T-cell therapy decreases serum prostate-specific antigen levels in prostate cancer, indicating the feasibility of CAR T-cell therapy in solid tumors [104,105,106]. Here, FOLH1 is linked to Familial prostate cancer.